Novavax (NASDAQ: NVAX) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Novavax to related companies based on the strength of its valuation, risk, analyst recommendations, earnings, institutional ownership, profitability and dividends.


This table compares Novavax and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novavax -1,006.00% -787.38% -53.89%
Novavax Competitors -4,022.62% -118.16% -43.86%

Risk & Volatility

Novavax has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, Novavax’s peers have a beta of 1.63, meaning that their average stock price is 63% more volatile than the S&P 500.

Earnings & Valuation

This table compares Novavax and its peers gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Novavax $21.04 million -$186.64 million -1.51
Novavax Competitors $207.80 million -$2.20 million -0.04

Novavax’s peers have higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings for Novavax and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax 0 6 2 0 2.25
Novavax Competitors 464 2206 6095 117 2.66

Novavax presently has a consensus price target of $3.35, indicating a potential upside of 188.79%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 2.48%. Given Novavax’s higher probable upside, equities research analysts plainly believe Novavax is more favorable than its peers.

Insider & Institutional Ownership

45.2% of Novavax shares are held by institutional investors. Comparatively, 47.0% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.0% of Novavax shares are held by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


Novavax peers beat Novavax on 9 of the 12 factors compared.

Novavax Company Profile

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Receive News & Stock Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related stocks with our FREE daily email newsletter.